62 related articles for article (PubMed ID: 11452450)
1. [Target molecules of anti-tumor drugs and cell checkpoints].
Sugimoto K
Rinsho Ketsueki; 2001 May; 42(5):356-8. PubMed ID: 11452450
[No Abstract] [Full Text] [Related]
2. Cell-cycle control in the face of damage--a matter of life or death.
Clarke PR; Allan LA
Trends Cell Biol; 2009 Mar; 19(3):89-98. PubMed ID: 19168356
[TBL] [Abstract][Full Text] [Related]
3. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
Potter AJ; Rabinovitch PS
Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract.
Bagchi D; Ray SD; Bagchi M; Preuss HG; Stohs SJ
Indian J Exp Biol; 2002 Jun; 40(6):717-26. PubMed ID: 12587719
[TBL] [Abstract][Full Text] [Related]
5. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
6. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
[TBL] [Abstract][Full Text] [Related]
7. New method for the detection of reactive oxygen species in anti-tumoural activity of adriamycin: a comparison between hypoxic and normoxic cells.
Rharass T; Vigo J; Salmon JM; Ribou AC
Free Radic Res; 2008 Feb; 42(2):124-34. PubMed ID: 18297605
[TBL] [Abstract][Full Text] [Related]
8. UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.
Rapisarda A; Melillo G
Oncogene; 2007 Oct; 26(48):6875-84. PubMed ID: 17496931
[TBL] [Abstract][Full Text] [Related]
9. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment.
Skladanowski A; Bozko P; Sabisz M
Chem Rev; 2009 Jul; 109(7):2951-73. PubMed ID: 19522503
[No Abstract] [Full Text] [Related]
10. Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells.
Jänicke RU; Engels IH; Dunkern T; Kaina B; Schulze-Osthoff K; Porter AG
Oncogene; 2001 Aug; 20(36):5043-53. PubMed ID: 11526489
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
Koceva-Chyła A; Jedrzejczak M; Skierski J; Kania K; Jóźwiak Z
Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
[TBL] [Abstract][Full Text] [Related]
12. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.
Gatti L; Supino R; Perego P; Pavesi R; Caserini C; Carenini N; Righetti SC; Zuco V; Zunino F
Cell Death Differ; 2002 Dec; 9(12):1352-9. PubMed ID: 12478472
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Verheul HM; Qian DZ; Carducci MA; Pili R
Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
[TBL] [Abstract][Full Text] [Related]
16. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
[TBL] [Abstract][Full Text] [Related]
17. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
Baptiste N; Friedlander P; Chen X; Prives C
Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
[TBL] [Abstract][Full Text] [Related]
18. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C
J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.
Mizutani H; Tada-Oikawa S; Hiraku Y; Kojima M; Kawanishi S
Life Sci; 2005 Feb; 76(13):1439-53. PubMed ID: 15680309
[TBL] [Abstract][Full Text] [Related]
20. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
